UBS Group
NNNN

UBS Group’s Anbio Biotechnology NNNN Stock Holding History

UBS Group’s Portfolio NNNN Stock Details NNNN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$163K Buy
6,339
+3,490
+122% +$91.1K ﹤0.01% 6750
2025
Q4 		$85.7K Buy
2,849
+1,889
+197% +$51.9K ﹤0.01% 6980
2025
Q3 		$35.8K Sell
960
-9,735
-91% -$437K ﹤0.01% 7787
2025
Q2 		$339K Buy
10,695
+4,957
+86% +$47.4K ﹤0.01% 6345
2025
Q1 		$42.8K Buy
+5,738
New +$39.2K ﹤0.01% 7698

Other funds holding NNNN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFS
Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

UBS Group's NNNN Position: Q1 2026 in Review

UBS Group increased its Anbio Biotechnology (NNNN) stake by 122% in Q1 2026, buying an estimated $91.1K and bringing the position to 6,339 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #6750.

UBS Group first reported a position in NNNN in Q1 2025 and has held it in 5 quarters since. The position peaked at $339K in Q2 2025. 8 funds tracked by Wall St. Rank hold NNNN as of Q1 2026.

  • UBS Group held 6,339 shares of Anbio Biotechnology worth $163K as of Q1 2026.
  • UBS Group bought 3,490 Anbio Biotechnology shares in Q1 2026, an estimated $91.1K.
  • Anbio Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6750 holding.
  • UBS Group first reported a position in Anbio Biotechnology in Q1 2025 and has held it in 5 quarters since.
  • UBS Group's Anbio Biotechnology position peaked at $339K in Q2 2025.
  • 8 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.